A Real-World Pharmacovigilance Analysis of HER2 Inhibitor-Induced Cardiovascular Toxicity
Oncology · 2026
DOI: 10.1159/000553521 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology, 2026. Verfasst von Jianhui Yao und 6 weiteren Autor:innen. Beteiligte Einrichtung: West China Hospital Sichuan University, Meishan Hospital, Meishan, China. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Cardiovascular Diseases, Protein Kinase Inhibitors, Antineoplastic Agents. Die Arbeit nennt 43 Literaturangaben.
Abstract (Originalsprache)
Introduction
With the widespread use of human epidermal growth factor receptor 2 (HER2) inhibitors in cancer treatment, cardiovascular diseases induced by these agents have become a significant adverse event.
Methods
We retrieved reports of HER2 inhibitor-induced cardiovascular adverse events (CVAEs) from the FDA Adverse Event Reporting System(FAERS) database, covering the period from the first quarter of 2004 to the fourth quarter of 2024. Disproportionality analyses were conducted using reporting odds ratios and proportional reporting ratios. The signals of HER2 inhibitor-related CVAEs were evaluated at both the standardized MedDRA query and preferred term levels.
Results
A total of 12,698 reports associated with CVAEs were identified, with HER2 inhibitors listed as the primary suspected drug, involving 12,398 patients. Most cases were observed in individuals aged 45 years and older, with a notably higher proportion in women. The time to onset of HER2 inhibitor-induced CVAEs showed certain variability. Trastuzumab exhibited higher cardiovascular toxicity compared with other HER2 inhibitors. In general, monoclonal antibodies demonstrated greater cardiovascular toxicity, whereas antibody-drug conjugates and HER2-tyrosine kinase inhibitors displayed comparable and lower effects.
Conclusion
This pharmacovigilance analysis reveals a strong association between HER2 inhibitors and CVAEs, providing valuable insights for their prevention and clinical management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- West China Hospital Sichuan University, Meishan Hospital, Meishan, China.
- Department of Cardiology, Meishan People's Hospital, Meishan, China.
- Department of Pharmacy, The Affiliated Hospital, Southwest Medical University, Luzhou, China.
- Department of Clinical Pharmacy, School of Pharmacy, Southwest Medical University, Luzhou, China.
- Department of Pharmacy, West China Hospital Sichuan University Jintang Hospital · Jintang First People's Hospital, Chengdu, China, 15883056860@163.com.
- Department of Pharmacy, The Affiliated Hospital, Southwest Medical University, Luzhou, China, meilzhou@swmu.edu.cn.
Zitieren
APA
Yao, J., Tao, C., Chen, W., Li, R., Wang, K., Shang, J., & Zhou, M. (2026). A Real-World Pharmacovigilance Analysis of HER2 Inhibitor-Induced Cardiovascular Toxicity. Oncology. https://doi.org/10.1159/000553521
Vancouver
Yao J, Tao C, Chen W, Li R, Wang K, Shang J, et al. A Real-World Pharmacovigilance Analysis of HER2 Inhibitor-Induced Cardiovascular Toxicity. Oncology. 2026. doi:10.1159/000553521
BibTeX
@article{Yao2026,
author = {Yao, Jianhui and Tao, Chao and Chen, Weiyi and Li, Ruixiao and Wang, Ke and Shang, Jinlu and Zhou, Meiling},
title = {A Real-World Pharmacovigilance Analysis of HER2 Inhibitor-Induced Cardiovascular Toxicity},
journal = {Oncology},
year = {2026},
doi = {10.1159/000553521}
}
EUVIMED